Company profile for Cullinan Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Cullinan Therapeutics, our approach to drug discovery and development is modality-agnostic and targeted, aiming to create molecules that could significantly improve patients' lives. Formerly known as Cullinan Oncology, our company was established in 2016 and is based in the vibrant science and technology hub of Cambridge, Massachusetts. With a dedicated team boasting diverse backgrounds and expertise, we foster a collaborat...
At Cullinan Therapeutics, our approach to drug discovery and development is modality-agnostic and targeted, aiming to create molecules that could significantly improve patients' lives. Formerly known as Cullinan Oncology, our company was established in 2016 and is based in the vibrant science and technology hub of Cambridge, Massachusetts. With a dedicated team boasting diverse backgrounds and expertise, we foster a collaborative culture deeply rooted in our commitment to following the science. This collective effort drives us to explore new solutions and push the boundaries of innovation in healthcare.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, MA 02142
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196843/0/en/Cullinan-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CLN-049-a-Novel-FLT3xCD3-T-Cell-Engager-in-Relapsed-Refractory-Acute-Myeloid-Leukemia.html

GLOBENEWSWIRE
01 Dec 2025

https://www.prnewswire.com/news-releases/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cel-302621302.html

PR NEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184394/0/en/Cullinan-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences-and-Host-Analyst-and-Investor-Event-at-2025-ASH-Annual-Meeting.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179412/0/en/Cullinan-Therapeutics-to-Showcase-New-Data-Demonstrating-Compelling-Clinical-Activity-for-CLN-049-a-Novel-FLT3xCD3-T-Cell-Engager-in-AML-Patients-in-an-Oral-Presentation-at-the-67t.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/25/3174169/0/en/Cullinan-Therapeutics-Shares-Additional-Preclinical-B-Cell-Depletion-Data-for-CLN-978-Supporting-Clinical-Development-Across-Multiple-Autoimmune-Diseases-at-ACR-Convergence-2025.html

GLOBENEWSWIRE
25 Oct 2025

https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-in-patients-with-nsclc-with-egfr-mutations-and-active-brain-metastases-at-the-esmo-congress-2025-302581514.html

PR NEWSWIRE
13 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty